PRKDC and neoplasm: For instance, studies have reported the existence of a DNA-PK-Chk1 backup pathway that can mediate resistance to ATR inhibitors in tumor cells with lower levels of replication stress [154], arguing for the simultaneous targeting of ATR with DNA-PK or Chk1.